Untreated rabies infections are nearly 100% lethal and kill over 50,000 people every year. Although rabies vaccines and treatments are available, they are suboptimal. Rabies vaccines do not elicit a long-lasting immune response, and rabies treatments, which consist of a combination of human rabies immunoglobulin (pooled serum from vaccinees) administered at the site of infection and a series of rabies vaccines, are often prohibitively expensive.
In order to design a long-lasting rabies vaccine, we need to better understand how human rabies antibodies interact with rabies virus. This project aims to isolate antibodies and antibody producing cells from human blood in order to understand the human rabies immune response and to develop anti-rabies therapeutic antibodies.
Eligibility Criteria (one or more):
- You are a generally healthy male or female, over 18 years of age.
- You have had a rabies vaccine in the last 6-12 months